Gilead Sciences, Inc.

Novartis Ag

Britton Kenneth Corkey

Jeff A Zablocki

Michael Graupe

Xiaofen Li

Robert H Jiang

Elfatih O Elzein

Rao V Kalla

Thao Perry

Gregory Notte

Dmitry Koltun

Eric Q Parkhill

Ruben Martinez

Chandrasekar Venkataramani

Juan A Guerrero

Tetsuya Kobayashi

Kristyna M Elbel

Lawrence S Melvin, Jr

Keith Koch

Samuel E Metobo

David Sperandio

Hai Yang

Mark J Bartlett

Jennifer Leigh Cosman

Jinfa Du

Michael R Mish

Gregory F Chin

Evangelos Aktoudianakis

Sophie Shevick

Qian Zhao

Michael Robert Turner

Rick Andrew Lee

David C Tully

Joseph Michael Young

Naomi S Rajapaksa

Manuel Munoz

Robert Joseph Moreau

Yipin Lu

Galen Paul Shearn-Nance

Zef Konst

Suet Chung Yeung

Julian Andrew Codelli

Joshua J Van Veldhuizen

Kerim Babaoglu

Jennifer Alissa Loyer-Drew

Eifatih Elzein

Elfatih Elzein

Jeff Zablocki

Gregory Chin

Michael Mish

Kristyna Elbel

Rick Lee

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Antiviral pyrazolopiridinone compounds

Antiviral pyrazolopyridinone compounds

Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed: 

Therapeutic heterocyclic compounds

Compounds having the following Formula (I), or a pharmaceutically acceptable salt or pharmaceutically acceptable tautomer thereof, and methods of their use and preparation are disclosed: 

The present invention relates to compounds of Formula (I): wherein X, X, X, X, X, X, X, X, R, R, Rare defined above. The compounds have apoptosis signal-regulating kinase ('ASK1') inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

Apoptosis signal-regulating kinase inhibitors

Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed: 

The present invention relates to compounds of Formula (I): wherein X, X, X, X, X,, R, Rare as defined above. The compounds have apoptosis signal-regulating kinase ('ASK1') inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, COPD, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare described herein.

Benzimidazole derivatives as bromodomain inhibitors

The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R, R, R, R, R, and Rare as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

Benzimidazole and imadazopyridine carboximidamide compounds

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

Fused heterocyclic compounds as ion channel modulators

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R, X, X, Y and Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z, Z, Z, Z, X, Y, R, Rand Rare as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

The present invention relates to compounds of Formula (I): wherein X, X, X, X, X, X, X, X, R, R, Rare as defined above. The compounds have apoptosis signal-regulating kinase ('ASK1') inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).

Growing community of inventors

Redwood City, CA, United States of America

Britton Kenneth Corkey